Key result
Low molecular weight heparin has emerged as a safe and effective alternative to intravenous unfractionated heparin for periprocedural bridging in chronically anticoagulated patients.
Why the study?
Is LMWH a safe and effective alternative to intravenous unfractionated heparin for periprocedural bridging in chronically anticoagulated patients?
Is LMWH a safe and effective alternative to intravenous unfractionated heparin for periprocedural bridging in chronically anticoagulated patients?
LMWH is a safe and effective alternative to unfractionated heparin for periprocedural bridging in patients on chronic oral anticoagulation.
LMWH may offer clinicians a practical bridging alternative; leaves open need for randomized confirmation in indicated patients.
Periprocedural bridging of the patient on long-term anticoagulation is indicated in nonvalvular atrial fibrillation with additional risk factors, prosthetic heart valves, venous thromboembolism within 3 months of the procedure, and hypercoagulable conditions requiring oral anticoagulation. Until recently, intravenous unfractionated heparin was used for bridging. LMWH has now emerged as a safe and effective bridging alternative.
No takes yet. Share an insight, caveat, or question.
Piazza et al. (2003) conducted a review in Chronically anticoagulated patients requiring periprocedural management. Low molecular weight heparin (LMWH) vs. Intravenous unfractionated heparin was evaluated. Low molecular weight heparin has emerged as a safe and effective alternative to intravenous unfractionated heparin for periprocedural bridging in chronically anticoagulated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: